title: Do formulation switches exacerbate existing medical illness? Results of an open-label transition to orally disintegrating risperidone tablets.
abstract: BACKGROUND
  Orally disintegrating risperidone tablets (Risperdal* M-TABs*) present an alternative method of drug delivery that may benefit physicians struggling to treat non-compliant patients, since it begins to dissolve within 5 s, preventing tablet cheeking or spitting.
  
  
  OBJECTIVE
  To evaluate safety and maintenance of effect in symptomatically stable patients transitioned from compressed risperidone tablets to orally disintegrating risperidone tablets.
  
  
  METHODS
  This open-label, multi-centre study enrolled 82 adults from four diagnostic groups (major depressive disorder (MDD), n = 25; bipolar disorder (BP), n = 21; dementia (DE), n = 20; schizophrenia (SZ), n = 16). Patients were switched from their previous dosage of compressed tablets (0.5, 1.0, 2.0, 3.0, or 4.0 mg/day) to an equivalent dosage of orally disintegrating risperidone and followed for 4 weeks. The primary effectiveness parameter evaluated was the Clinical Global Impression-Severity (CGI-S) scale.
  
  
  RESULTS
  Most patients (24/25 MDD; 20/21 BP; 17/18 DE; 14/15 SZ) improved by 1 point on CGI-S from baseline or experienced no change at endpoint. Adverse events (AEs) occurring in any group at a > or =10% incidence included headache (19%) and pharyngolaryngeal pain (10%), reported in the BP group only.
  
  
  CONCLUSIONS
  Patients stabilized on compressed risperidone tablets transitioned to the equivalent dose of orally disintegrating risperidone tablets with continued maintenance of effect, no decompensation and with minimal side effects.
authors.affiliation: University of Alberta Hospital, Edmonton, Alberta, Canada. pchue@ualberta.ca
authors.forename: Pierre
authors.initials: P
authors.lastname: Chue
authors.forename: Rosanna S
authors.initials: RS
authors.lastname: Prinzo
authors.forename: Carin E
authors.initials: CE
authors.lastname: Binder
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy*; D008875:Middle Aged; D018967:Risperidone / Q000008:administration & dosage / Q000627:therapeutic use*; D012995:Solubility; D013607:Tablets
chemical_list: D014150:Antipsychotic Agents; D013607:Tablets; D018967:Risperidone